Prognosis in meningoencephalitis of unknown origin in dogs: Risk factors associated with survival, clinical relapse, and long-term disability

被引:3
作者
Goncalves, Rita [1 ,2 ,4 ]
De Decker, Steven [3 ]
Walmsley, Gemma [1 ,2 ]
Maddox, Thomas W. [1 ,2 ]
机构
[1] Univ Liverpool, Small Anim Teaching Hosp, Dept Vet Sci, Neston, England
[2] Univ Liverpool, Inst Lifecourse & Med Sci, Dept Musculoskeletal & Ageing Sci, Neston, England
[3] Univ London, Royal Vet Coll, Dept Clin Sci & Serv, Hatfield, England
[4] Univ Liverpool, Small Anim Teaching Hosp, Neston CH64 7TE, Cheshire, England
关键词
canine; mortality; MUO; outcome; prognosis; relapse; FIBRILLARY ACIDIC PROTEIN; MULTIPLE-SCLEROSIS; NECROTIZING MENINGOENCEPHALITIS; CLUSTER SEIZURES; PREDICTORS; EPILEPSY; THERAPY; MS;
D O I
10.1111/jvim.17037
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background Meningoencephalitis of unknown origin (MUO) comprises a group of noninfectious inflammatory diseases affecting the central nervous system of dogs. Previous studies have reported individual risk factors for survival but prognostication for MUO remains challenging. Objectives Identify clinical prognostic variables in dogs with MUO. Animals A retrospective study of 447 dogs presented to 2 UK referral hospitals and diagnosed with MUO. Methods Medical records of dogs diagnosed with MUO were retrospectively reviewed. Multivariable logistic regression was used for the identification of risk factors for survival and Cox proportional hazards analysis for the identification of risk factors for clinical relapse. Results Eighty-two percent (366/447) of dogs with presumptive MUO survived to discharge and 63.5% (284/447) were alive at 6 months; 36% of the latter (103/284) had persistent neurological deficits. Breed (pugs; P = .03), epileptic seizures (P < .001), paresis (P < .001), and higher neurodisability scale (NDS) score (P < .001) at presentation were negatively associated with survival to 6 months. Dogs with persistent deficits had higher NDS scores on presentation (P = .001). Median follow-up time was 11 months (interquartile range [IQR], 1-24) and 50.6% (160/316) relapsed during treatment (median time to relapse, 7 months; IQR, 2-15). Incomplete resolution of the clinical signs during the 6 months after diagnosis (P < .001), higher NDS score (P < .001), and longer duration of the clinical signs (P < .001) were associated with relapse. Conclusions and Clinical Importance Knowledge of risk factors associated with survival, incomplete recovery and clinical relapse in MUO can help guide monitoring and treatment and improve owner communications regarding prognosis for this debilitating disease.
引用
收藏
页码:1583 / 1590
页数:8
相关论文
共 41 条
  • [1] A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials
    Amato, MP
    Ponziani, G
    Bartolozzi, ML
    Siracusa, G
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 168 (02) : 96 - 106
  • [2] Treatment With Cytarabine at Initiation of Therapy With Cyclosporine and Glucocorticoids for Dogs With Meningoencephalomyelitis of Unknown Origin Is Not Associated With Improved Outcomes
    Barber, Renee
    Downey Koos, Lauren
    [J]. FRONTIERS IN VETERINARY SCIENCE, 2022, 9
  • [3] Retrospective evaluation of combined mycophenolate mofetil and prednisone treatment for meningoencephalomyelitis of unknown etiology in dogs: 25 cases (2005-2011)
    Barnoon, Itai
    Shamir, Merav H.
    Aroch, Itamar
    Bdolah-Abram, Tali
    Srugo, Itai
    Konstantin, Lilach
    Chai, Orit
    [J]. JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE, 2016, 26 (01) : 116 - 124
  • [4] Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
    Barro, Christian
    Healy, Brian C.
    Liu, Yanqing
    Saxena, Shrishti
    Paul, Anu
    Polgar-Turcsanyi, Mariann
    Guttmann, Charles R. G.
    Bakshi, Rohit
    Kropshofer, Harald
    Weiner, Howard L.
    Chitnis, Tanuja
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (01):
  • [5] Bateman SW, 1999, J AM VET MED ASSOC, V215, P1463
  • [6] Coates JR, 2007, J VET INTERN MED, V21, P100, DOI 10.1892/0891-6640(2007)21[100:PAATFT]2.0.CO
  • [7] 2
  • [8] Perspectives on Meningoencephalomyelitis of Unknown Origin
    Coates, Joan R.
    Jeffery, Nicholas D.
    [J]. VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 2014, 44 (06) : 1157 - +
  • [9] Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
    Confavreux, C
    Vukusic, S
    Adeleine, P
    [J]. BRAIN, 2003, 126 : 770 - 782
  • [10] A NECROTIZING MENINGOENCEPHALITIS OF PUG DOGS
    CORDY, DR
    HOLLIDAY, TA
    [J]. VETERINARY PATHOLOGY, 1989, 26 (03) : 191 - 194